48 related articles for article (PubMed ID: 38594266)
21. Cancer Statistics, 2021.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2021 Jan; 71(1):7-33. PubMed ID: 33433946
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients.
Feng F; Wu X; Shi X; Gao Q; Wu Y; Yu Y; Cheng Q; Li B; Yi B; Liu C; Hao Q; Zhang L; Gao C; Jiang X
Int J Clin Oncol; 2021 Apr; 26(4):717-727. PubMed ID: 33387086
[TBL] [Abstract][Full Text] [Related]
23. H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Bosgana P; Nikou S; Dimitrakopoulos FI; Logotheti S; Tzelepi V; Kalophonos C; Bravou V; Kourea E; Sampsonas F; Zolota V
Curr Mol Pharmacol; 2021; 14(6):1028-1036. PubMed ID: 32867667
[TBL] [Abstract][Full Text] [Related]
24. Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M; Calvo E
Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
[TBL] [Abstract][Full Text] [Related]
25. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
26. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors.
Rawla P; Sunkara T; Barsouk A
Prz Gastroenterol; 2019; 14(2):89-103. PubMed ID: 31616522
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
29. Structural insights into trans-histone regulation of H3K4 methylation by unique histone H4 binding of MLL3/4.
Liu Y; Qin S; Chen TY; Lei M; Dhar SS; Ho JC; Dong A; Loppnau P; Li Y; Lee MG; Min J
Nat Commun; 2019 Jan; 10(1):36. PubMed ID: 30604749
[TBL] [Abstract][Full Text] [Related]
30. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Xiong W; Deng H; Huang C; Zen C; Jian C; Ye K; Zhong Z; Zhao X; Zhu L
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):454-463. PubMed ID: 30385408
[TBL] [Abstract][Full Text] [Related]
31.
Cho SJ; Yoon C; Lee JH; Chang KK; Lin JX; Kim YH; Kook MC; Aksoy BA; Park DJ; Ashktorab H; Smoot DT; Schultz N; Yoon SS
Clin Cancer Res; 2018 Dec; 24(24):6556-6569. PubMed ID: 30108106
[TBL] [Abstract][Full Text] [Related]
32. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.
Li T; Fan J; Wang B; Traugh N; Chen Q; Liu JS; Li B; Liu XS
Cancer Res; 2017 Nov; 77(21):e108-e110. PubMed ID: 29092952
[TBL] [Abstract][Full Text] [Related]
33. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Le DT; Durham JN; Smith KN; Wang H; Bartlett BR; Aulakh LK; Lu S; Kemberling H; Wilt C; Luber BS; Wong F; Azad NS; Rucki AA; Laheru D; Donehower R; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Greten TF; Duffy AG; Ciombor KK; Eyring AD; Lam BH; Joe A; Kang SP; Holdhoff M; Danilova L; Cope L; Meyer C; Zhou S; Goldberg RM; Armstrong DK; Bever KM; Fader AN; Taube J; Housseau F; Spetzler D; Xiao N; Pardoll DM; Papadopoulos N; Kinzler KW; Eshleman JR; Vogelstein B; Anders RA; Diaz LA
Science; 2017 Jul; 357(6349):409-413. PubMed ID: 28596308
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.
Bupathi M; Wu C
J Gastrointest Oncol; 2016 Oct; 7(5):713-720. PubMed ID: 27747085
[TBL] [Abstract][Full Text] [Related]
35. Robust enumeration of cell subsets from tissue expression profiles.
Newman AM; Liu CL; Green MR; Gentles AJ; Feng W; Xu Y; Hoang CD; Diehn M; Alizadeh AA
Nat Methods; 2015 May; 12(5):453-7. PubMed ID: 25822800
[TBL] [Abstract][Full Text] [Related]
36. Mutational landscape and significance across 12 major cancer types.
Kandoth C; McLellan MD; Vandin F; Ye K; Niu B; Lu C; Xie M; Zhang Q; McMichael JF; Wyczalkowski MA; Leiserson MDM; Miller CA; Welch JS; Walter MJ; Wendl MC; Ley TJ; Wilson RK; Raphael BJ; Ding L
Nature; 2013 Oct; 502(7471):333-339. PubMed ID: 24132290
[TBL] [Abstract][Full Text] [Related]
37. MLL translocations, histone modifications and leukaemia stem-cell development.
Krivtsov AV; Armstrong SA
Nat Rev Cancer; 2007 Nov; 7(11):823-33. PubMed ID: 17957188
[TBL] [Abstract][Full Text] [Related]
38. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
[TBL] [Abstract][Full Text] [Related]
39. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
40. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
